Meet our partners
Founding Partner 2013-16
SR One
SR One is the independent corporate venture capital arm of GlaxoSmithKline. They invest globally in emerging life science companies that are pursuing innovative science with significant impact on medical care. SR One has invested over $830MM in the health care industry. We've partnered up with the Oxbridge Biotech Roundtable because of our shared missions of catalysing entrepreneurship. Together with OBR, we firmly believe that we can have a positive impact on human health by supporting visionary founders. We see OneStart as a vehicle to that end. Read more at srone.com
News

Feb 2016 eFFECTOR THERAPEUTICS increases its series B financing round to $56M 

Dec 2015 Navitor Pharmaceuticals Announces $33 Million Series B Financing

Dec 2015 OneStart surges with 750 startups from 50+ countries


OneStart Europe Vision Film 2016

  • Matthew Foy, Partner, SR One
  • Dan Perez, CEO & Founder, Oxbridge Biotech Roundtable 
  • Nooman Haque, Director of Life Sciences, Silicon Valley Bank
  • Richard Mason, Head of Johnson & Johnson Innovation London, Johnson & Johnson 
  • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation - JJDC
  • Sarah Haywood, CEO, MedCity 
  • Matthias Essenpreis, CTO (Diagnostics), F-Hoffman-La Roche Ltd. 
  • Rachel Moss, Associate Principal, McKinsey and Company 
  • Claire Brown, Investment Manager, Alderley Park Ventures / BioCity 
  • Lynne Murray, Partnering and Strategy, MedImmune
  • Aric Orbach, Head of Pharmacology, Teva Pharmaceutical Industries 
  • Stephen Reese, Partner, Olswang LLP 
  • Ilan Zipkin, Investment Director, Takeda Ventures Inc.


From the OneStart London Bootcamp 2016

Panel Discussion

Panel Discussion: Investors


  • Matthew Foy, Partner, SROne (Chair)
  • Deborah Harland, PhD, MBA, Partner, SROne
  • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures Inc.
  • Nihal Sinha, MRCP, Senior Associate, F-Prime Capital Partners
  • Hasan Goker, PhD, Senior Investment Director, MS Ventures


From the OneStart San Francisco Bootcamp 2016

Seminar

Seminar: Writing a Good Business Plan - Matthew Foy

  • Matthew Foy, Partner, SR One 


Panel Discussion

Panel Discussion: Business Model Innovation

  • Daniel Perez, Founder & CEO, Oxbridge Biotech Roundtable (Chair)
  • Jens Eckstein, PhD, President, SR One 
  • Lucy Perez, PhD, Partner, McKinsey & Company


Panel Discussion: Investors

  • Matthew Foy, Partner, SR One (Chair)
  • Cayce Denton, VP, TPG Biotech 
  • Jenny Rooke, PhD, Manging Director, 5 Prime Ventures
  • Tracy Saxton, PhD, Investment Director, Roche Venture Fund
  • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures


Panel Discussion: Experienced Entrepreneurs

  • Jens Eckstein, PhD, President, SROne (Chair)
  • Martin Barbler, CEO, Princia Biopharma
  • Greg Yap, AB and MBA, Co-founder and CEO, Biodesy Inc.
  • Simon Greenwood, PhD, CBO, Allakos Inc.
  • Nancy Stagilano, PhD, CEO, True North Therapeutics Inc.


From the OneStart London Bootcamp 2015

Seminar

Seminar: Value - Matthew Foy


Click here to watch the full seminar


Panel Discussion

Panel Discussion: Experienced Entrepreneurs
  • Jens Eckstein, PhD, President, SR One (Chair)
  • Roger Bone, PhD, VP Transactions, Johnson & Johnson Innovation, London
  • Neill Mackenzie, PhD, CEO, Roji
  • Rod Richards, CEO, VHsquared
  • Andy Sandham, Partner, Syncona Partners


Panel Discussion: Life Science & Healthcare Investors
  • Matthew Foy, Partner, SR One (Chair)
  • Deborah Harland, PhD, MBA, Partner, SR One
  • Maina Bhaman, MBA, Director of Healthcare Investments, Imperial Innovations
  • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation – JJDC
  • Vishal Gulati, MD, Venture Partner, DFJ Esprit
  • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures
Mentors
Deborah Harland
Partner, SR One + more
I joined SR One in 2005 to establish the firm's European investment office. I have extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during more than 20 year tenure in the pharmaceutical industry. I am currently a member of the Board of Directors of Mission Therapeutics, Bicycle Therapeutics, Atopix Therapeutics, AtoxBio, f-star and VH Squared.
Jens Eckstein
President, SR One + more
I came to SR One from TVM Capital where I was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, I was a General Partner in TVMs Boston life sciences practice where I focused on earlier-stage investments. I am currently Chairman of the Board of Directors of Thrasos Therapeutics and a Director at Alios BioSciences. I was also the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company.
Matthew Foy
Partner, SR One + more
I joined SR One in 2011 to take the lead in investing SR One's UK biotech fund. Prior to joining SR One I worked as a consultant for Longbow Capital Partners in London, and before that I was a Vice President of Greenhill & Co, an M&A Investment Bank and Private Equity firm.
David Phillips
Partner, SR One + more
I joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. I bring a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. I have significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors.
Jill Carroll
Senior Associate, SR One + more
I joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, I was responsible for Corporate Development at Dynavax Technologies, where I was involved in multiple pharma partnering deals as well as substantial private and public financings. Previously, I was a consultant specializing in health care at Clearview Projects and Mercer Management Consulting.
Simeon J. George
Partner, SR One + more
I lead SR One's investment activities on the West Coast. Prior to joining SR One, I was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.
Vikas Goyal
Associate, SR One + more
I joined SR One in January 2011, after interning with SR One since 2009. Prior to joining SR One, I was a consultant at McKinsey & Co, a co-founder of Extera Partners, and a business development manager at Infinity Pharmaceuticals. Over my career, I have supported business and corporate development activities for nearly 50 large and small public, venture-backed, and angel funded life science companies.
Teams Mentored
Play - Semi-finalist WaveCap - Oxford, United Kingdom - Non-invasive neurostimulation for early onset seizure detection & treatment using novel machine learning algorithm on EEG